Vagus Nerve Stimulation and Opioid Withdrawal Pain

Transcutaneous cervical vagus nerve stimulation (tcVNS) may affect the autonomic state that travels with opioid withdrawal pain. That is the intriguing result from a 2025 pilot study. It is not evidence that the device treats withdrawal pain.

The study reported that changes in heart-rate variability (HRV) and respiratory pulse variability (RPV) tracked changes in pain ratings during stimulation. That pattern fits a biologically plausible idea: altering autonomic activity could alter pain experience. But the clinical comparison involved only 20 people, including nine who received active stimulation. The pain result reached conventional statistical significance, yet the study was far too small and confounded to guide care.

The pain signal came from nine treated participants

In the pilot by Gazi et al., participants undergoing opioid withdrawal received either active cervical stimulation with a gammaCore device or sham stimulation during a two-hour protocol. The active group's numerical rating scale (NRS) pain score fell by 0.8 points on average, with a standard deviation of 2.4. The sham group's score rose by 0.9 points. The between-group difference was therefore about 1.7 points, with p = 0.045.

That result deserves careful wording. A p value below 0.05 says the observed difference met the study's statistical threshold; it does not establish a reliable clinical effect. The active-group standard deviation was larger than its average improvement, so individual outcomes varied widely. The reported standardized effect, Cohen's d of about 0.71, falls in the conventional medium range, but estimates from nine treated people routinely swing high or low by chance.

The sham group's worsening further complicates the arithmetic. Opioid withdrawal can intensify over time, and an untreated increase in pain during a two-hour assessment would enlarge the apparent difference between groups even if active stimulation produced little direct analgesia. The study did not include a design that could cleanly separate the natural withdrawal trajectory from a treatment effect.

It also used only one pre/post pain-rating pair and reported no follow-up. A short-term change in self-reported pain could reflect analgesia, reduced arousal, distraction, changing craving, or the ordinary movement of withdrawal symptoms over time. The protocol included opioid cue exposure during stimulation, which makes the distinction harder: cue-induced stress and craving can affect both autonomic measures and pain ratings.

The biomarker result is plausible, but HRV is not a mechanism detector

The study's more interesting finding was the covariation between cardiorespiratory measures and pain. HRV describes variation in the intervals between heartbeats. Some HRV measures, especially high-frequency measures, often relate to parasympathetic activity. RPV captures variation tied to respiratory pulse signals. If pain fell as these measures changed during tcVNS, autonomic modulation is a reasonable hypothesis worth testing.

Researchers did not discover the HRV-pain relationship in this pilot. A 2022 systematic review by Forte et al. found that HRV indices were associated with experimental and clinical pain reactivity across diverse populations. Li et al. likewise found that autonomic measures tracked pain resilience across anticipation, pain experience, and recovery. Those findings make HRV a sensible measurement choice. They do not make a correlation during stimulation proof that vagal signaling caused pain relief.

The proposed pathway is neuroanatomically credible: vagal afferents could influence the nucleus tractus solitarius, then the locus coeruleus and descending noradrenergic systems that influence spinal pain processing. Human evidence in this area, however, does not directly trace that chain in people withdrawing from opioids. It supports plausibility, not confirmation.

HRV also responds to many inputs besides pain-modulating vagal activity. During opioid withdrawal, heart rate, blood pressure, sweating, distress, and breathing can all change. Research on the HRV-derived Analgesia Nociception Index illustrates the problem: high-frequency HRV can also predict a cardiovascular outcome, hypotension, in patients receiving spinal anesthesia for cesarean delivery. It is a physiological signal with several contributors, not a dedicated pain meter.

RPV is even more exploratory here. Participants wore COVID-19 masks throughout the protocol, directly affecting respiratory effort-belt measurements. That limitation weakens the study's most novel biomarker analysis.

Direction matters less cleanly than the theory implies

The strongest challenge to a simple "more parasympathetic activity equals less pain" story comes from Bakken et al.'s 2022 study of people treated for recurrent or persistent neck pain. In that setting, spinal manipulative therapy produced an acute pattern consistent with sympathetic upregulation: the LF/HF ratio increased while high-frequency power decreased. Pain reduction occurred alongside that pattern.

This does not refute the tcVNS pilot. The populations, interventions, and pain conditions differ. It does show why the direction of an HRV change cannot identify the analgesic mechanism by itself. Both sympathetic-oriented and parasympathetic-oriented changes can accompany lower pain in different contexts.

Noninvasive vagus stimulation can alter autonomic measures, but its effects depend on context and settings. A randomized crossover trial by Atanackov et al. found that frequency and pulse width substantially affected HRV responses to auricular stimulation in healthy adults. A sham-controlled crossover study by Sanchez-Perez et al. found that auricular vagus and median nerve stimulation reduced acute stress markers in healthy young adults.

Those studies support the general premise that noninvasive stimulation can affect autonomic state. They cannot validate the cervical gammaCore protocol used in opioid withdrawal. Auricular protocols typically target the cymba concha or tragus at lower frequencies, while the pilot used right-sided cervical stimulation with a 5 kHz sinusoidal carrier. Different placement and parameters may recruit different fibers and produce different effects.

Evidence for vagus stimulation in other pain conditions does not transfer automatically

There is controlled evidence that transcutaneous auricular VNS can reduce pain in other conditions. A 2025 randomized trial by Akkurt et al. reported reduced pain and improved mood in women with fibromyalgia receiving left or bilateral auricular stimulation. A 2025 randomized trial by Yildiz Kizkin et al. reported analgesic effects in people with primary dysmenorrhea. Yokota et al. also studied cymba-concha stimulation during experimental pain using the nociceptive withdrawal reflex, an objective measure, and reported correlations with parasympathetic indices.

These are useful reasons to study the question further. Fibromyalgia, menstrual pain, experimental nociceptive reflexes, and withdrawal-associated hyperalgesia are not interchangeable endpoints. Neither auricular stimulation nor its trial results can be treated as a proxy for cervical stimulation during opioid withdrawal.

What would answer the clinical question?

A confirmatory trial would need roughly 80 to 100 participants per group to test a clinically meaningful NRS difference of at least 1.5 points, assuming a standard deviation near 2.5. It should use a time-matched sham condition, stabilize or carefully account for withdrawal treatment during assessment, standardize time since last opioid use and opioid type, measure repeated pain outcomes, and follow participants beyond two hours.

It should also compare tcVNS with actual alternatives. The NSS-2 Bridge, a percutaneous electrical nerve field stimulation device, received FDA clearance in 2017 for managing opioid withdrawal symptoms. No published head-to-head trial has compared it with tcVNS, auricular VNS, or TENS for withdrawal pain. gammaCore is FDA-cleared for cluster headache and migraine prevention, not opioid withdrawal; use for withdrawal would be investigational and off-label.

The biomarker correlation is a legitimate early signal: autonomic state and pain changed together. It does not tell patients that tcVNS reliably relieves opioid withdrawal pain, nor does it identify parasympathetic upregulation as the proven cause.

For now, tcVNS belongs in better trials, not in self-directed withdrawal treatment plans. Opioid withdrawal can be medically serious, and evidence-based clinical care should set the plan.